Abstract
The role of histaminergic neurotransmission in the promotion of waking has been extensively studied in preclinical species. Appreciation for the role of histamine continues to expand with increasing understanding of the interaction of histamine within the broad network of neuromodulators that regulate sleep and wake. The effects of histamine on waking are transduced through the H1 and the H3 receptors in the central nervous system. Brain penetrant over-the-counter antihistamines comprised of antagonist actions at H1 receptors as well as varying degrees of antimuscarinic properties are marketed as sleep aids, based on their well-known daytime drowsiness side effects. The data supporting their use as sedatives, however, are not consistent. H3 receptors are presynaptic receptors that limit histamine release as well as that of monoamine neurotransmitters thought to participate in the maintenance of waking. In this review, we discuss the existing studies on various antihistamines and antagonists of the H1 receptor in the regulation of sleep in preclinical studies, normal subjects and in subjects with sleep disorders. In addition, we review the current data available on the use of ligands at H3 receptors for the modulation of sleep and wake.
Keywords: Histamine, antihistamines, sleep disorders, insomnia, excessive daytime sleepiness, EEG, histamine H1 receptor, histamine H3 receptor, wake-promoting agents
CNS & Neurological Disorders - Drug Targets
Title: Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders
Volume: 6 Issue: 1
Author(s): A. J. Barbier and M. J. Bradbury
Affiliation:
Keywords: Histamine, antihistamines, sleep disorders, insomnia, excessive daytime sleepiness, EEG, histamine H1 receptor, histamine H3 receptor, wake-promoting agents
Abstract: The role of histaminergic neurotransmission in the promotion of waking has been extensively studied in preclinical species. Appreciation for the role of histamine continues to expand with increasing understanding of the interaction of histamine within the broad network of neuromodulators that regulate sleep and wake. The effects of histamine on waking are transduced through the H1 and the H3 receptors in the central nervous system. Brain penetrant over-the-counter antihistamines comprised of antagonist actions at H1 receptors as well as varying degrees of antimuscarinic properties are marketed as sleep aids, based on their well-known daytime drowsiness side effects. The data supporting their use as sedatives, however, are not consistent. H3 receptors are presynaptic receptors that limit histamine release as well as that of monoamine neurotransmitters thought to participate in the maintenance of waking. In this review, we discuss the existing studies on various antihistamines and antagonists of the H1 receptor in the regulation of sleep in preclinical studies, normal subjects and in subjects with sleep disorders. In addition, we review the current data available on the use of ligands at H3 receptors for the modulation of sleep and wake.
Export Options
About this article
Cite this article as:
Barbier J. A. and Bradbury J. M., Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders, CNS & Neurological Disorders - Drug Targets 2007; 6 (1) . https://dx.doi.org/10.2174/187152707779940790
DOI https://dx.doi.org/10.2174/187152707779940790 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Peripheral Nervous System and the Pathogenesis of Prion Diseases
Current Molecular Medicine Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Current Drug Targets Compensatory Shift of Subcallosal Area and Paraterminal Gyrus White Matter Parameters on DTI in Patients with Alzheimer Disease
Current Alzheimer Research Non-Ceruloplasmin Copper Distinguishes A Distinct Subtype of Alzheimer’s Disease: A Study of EEG-Derived Brain Activity
Current Alzheimer Research Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Neovascular Age-Related Macular Degeneration and its Association with Alzheimer’s Disease
Current Aging Science Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
CNS & Neurological Disorders - Drug Targets Elimination of the Causes of Poor Sleep Underlying Delirium is a Basic Strategy to Prevent Delirium
Current Molecular Pharmacology Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer
Current Alzheimer Research Advent of Proteomic Tools for Diagnostic Biomarker Analysis in Alzheimer’s Disease
Current Protein & Peptide Science Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer’s Disease
Current Medicinal Chemistry The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research